Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ

Dow Jones

06/23

By Xavier Martinez

Shares of Definium Therapeutics surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial.

The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark.

DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April.

Stifel analysts said the results "exceeded expectations with clear and highly robust efficacy" in a research note.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

June 22, 2026 18:40 ET (22:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2645032910"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645032910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645032910?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645032910","market":"other","top_or_hot":-1,"title":"Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Xavier Martinez \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/DFTX\">Definium Therapeutics</a> surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial. \n</p>\n<p>\n     The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark. \n</p>\n<p>\n     DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/SFB\">Stifel</a> analysts said the results \"exceeded expectations with clear and highly robust efficacy\" in a research note. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnder the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-23 06:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Xavier Martinez \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/DFTX\">Definium Therapeutics</a> surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial. \n</p>\n<p>\n     The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark. \n</p>\n<p>\n     DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/SFB\">Stifel</a> analysts said the results \"exceeded expectations with clear and highly robust efficacy\" in a research note. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645032910","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645032910","pubTimestamp":1782168000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Definium Therapeutics surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial.The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark.DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April.Stifel analysts said the results \"exceeded expectations with clear and highly robust efficacy\" in a research note.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics","BK4007":"制药"},"translate_title":"低调：Definium股价受到强劲迷幻业绩的推动——《华尔街日报》","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":0.9},"content_text":"By Xavier Martinez \n\n\n     Shares of Definium Therapeutics surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial. \n\n\n     The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark. \n\n\n     DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April. \n\n\nStifel analysts said the results \"exceeded expectations with clear and highly robust efficacy\" in a research note. \n\n\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 18:40 ET (22:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}